Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

Vascular endothelial growth factor (VEGF) plays the most important role in regulating tumor-related angiogenesis and is often highly expressed in human cancers making it a preferred target for antitumor therapy [1,2]. With the introduction of VEGF inhibitors for cancer treatment, new class-specific adverse events (AEs) for these drugs have been observed, including perforations, bleeding, thromboembolic events, hypertension, and proteinuria [3,4]. Skin-related AEs are also often associated with the anti-VEGF small-molecule tyrosine kinase inhibitors sorafenib and sunitinib although these effects are not related directly to VEGF inhibition [3,5].

Source: Lung Cancer - August 12, 2015 Category: Cancer & Oncology Authors: Martin Reck, Anders Mellemgaard, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Ying Cheng, Kostas Zarogoulidis, Alexander Luft, Jaafar Bennouna, José Barrueco, Hesham Aboshady, Julia Hocke, Rolf Kaiser, Jean-Yves Douillard, for the LUME-Lung 1 Stud Source Type: research